<DOC>
	<DOCNO>NCT01880658</DOCNO>
	<brief_summary>RATIONALE : Surgical resection adjuvant therapy become main treatment resectable colorectal cancer . Treatment current strategy , however , recurrent rate high stage IIIC R0 resect stage IV . The efficacy safety maintenance therapy capecitabine still unknown . PURPOSE : This single arm study explore surgical resection adjuvant chemotherapy follow maintenance therapy capecitabine see efficacy safety , investigate effect maintenance therapy stage IIIC R0 resect stage IV colorectal cancer .</brief_summary>
	<brief_title>Phase II Study Maintenance Capecitabine Treat Resectable Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES Primary evaluate disease free survival rate three year patient stage IIIC resectable stage IV colorectal cancer treat maintenance capecitabine . Secondary 1 . Evaluate survival time patient treat regimen . 2 . Correlate genetic pattern presence absence specific tissue biomarkers response prognosis patient treat regimen . 3 . Determine quality life ( QOL ) patient treat maintenance capecitabine versus chemotherapy termination . 4 . Determine toxic effect maintenance regimens patient . 5 . Determine convenience care patient treat maintenance regimen . OUTLINE : This single arm , single-enter study . Patients receive therapy . Patients undergo R0-R1 resection receive adjuvant chemotherapy oxaliplatin fluorouracil ( 5FU ) folinic acid（FOLFOX）or oxaliplatin oxaliplatin capecitabine ( capox ) less 4 month . Radiotherapy may apply patient rectal cancer clinician suspect necessary . Then patient receive oral capecitabine 12 month maintenance . Quality life assess completion adjuvant treatment , completion maintenance chemotherapy , 1 year maintenance chemotherapy . After completion adjuvant treatment , patient follow every 3 month 2 year , every 6 month 3years . PROJECTED ACCRUAL : A total 100 patient accrue study within 3 year . Eligibility Ages Eligible Study : 18-80 Years old Genders Eligible Study : Both Accepts Healthy Volunteers : No</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Diagnosis Adenocarcinoma colon rectum 2 . Age:1880 year old 3 . Received curative resection diagnose colorectal cancer , postoperative stage : IIIC OR IV ( R0 resect ) 4 . Adjuvant chemotherapy mFOLFOX6 XELOX four month 5.15 day prior recruit , meet follow criterion : Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN Aspartate transaminase ≤ 2.5 time ULN Alanine transaminase ≤ 2.5 time ULN No hepatic disease would preclude study treatment followup No uncontrolled coagulopathy Renal Creatinine clearance &gt; 50 mL/min No renal disease would preclude study treatment followup 6.The ECOG score : 0～1 1 . Other colorectal cancer ( i.e.sarcoma , lymphoma , carcinoid , squamous cell carcinoma , cloacogenic carcinoma ) 2 . Synchronous cancer site 3 . Hypersensitivity capecitabine 4 . No More 4 week since prior participation investigational drug study 5 . Clear indication involvement pelvic side wall image With distant metastasis 6 . History invasive rectal malignancy , regardless diseasefree interval Fertile patient must use effective contraception 7 . Uncontrolled hypertension 8 . Cardiovascular disease would preclude study treatment followup 9 . Lack upper gastrointestinal tract integrity malabsorption syndrome，active upper gastrointestinal tract bleed 10 . Pregnant nursing , Fertile patient use effective contraception 11 . Other malignancy within past 5 year except effectively treat squamous cell basal cell skin cancer , melanoma situ , carcinoma situ cervix , carcinoma situ colon rectum 12 . No psychiatric addictive disorder , condition , opinion investigator , would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Maintenance therapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>Post-operation</keyword>
</DOC>